Adverse Event (AE) Management With Pomalidomide (POM)+ Low-Dose Dexamethasone (LoDEX) in the STRATUS (TM) Trial: A Phase 3b Study Evaluating Safety and Efficacy in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM)
Adverse Event (AE) Management With Pomalidomide (POM)+ Low-Dose Dexamethasone (LoDEX) in the STRATUS (TM) Trial: A Phase 3b Study Evaluating Safety and Efficacy in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM)
Languages of Item:
English
Abstract:
Empty abstract
Publication year:
2015
Authors:
Cavo, M Dimopoulos, MA Moreau, P Palumbo, A Corradini, P Weisel, K Ocio, E Doyen, C Anttila, P Raymakers, R others
